FibroBiologics, Inc. Common Stock
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications. The company was founded in 2021 and is based in Houston, Texas.
FibroBiologics, Inc. Common Stock (FBLG) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -31.776x
Based on the latest financial reports, FibroBiologics, Inc. Common Stock (FBLG) has a cash flow conversion efficiency ratio of -31.776x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.97 Million) by net assets ($125.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
FibroBiologics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how FibroBiologics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
FibroBiologics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of FibroBiologics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Seni Jaya Corporation Bhd
KLSE:9431
|
0.050x |
|
Enwell Energy plc
PINK:RGPMF
|
0.008x |
|
Jeonjinbio Co. Ltd
KQ:110020
|
0.018x |
|
SaintMed Public Company Limited
BK:SMD
|
0.073x |
|
HOLALUZ-CLIDOM SA EO 003
F:4H2
|
N/A |
|
Seneca Financial Corp
PINK:SNNF
|
0.002x |
|
Silver Grant International Holdings Group Limited
F:YSG
|
-0.035x |
|
Workhorse Group Inc
NASDAQ:WKHS
|
-0.343x |
Annual Cash Flow Conversion Efficiency for FibroBiologics, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of FibroBiologics, Inc. Common Stock from 2022 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $2.73 Million | $-11.90 Million | -4.351x | +14.82% |
| 2024-06-30 | $1.25 Million | $-6.40 Million | -5.109x | -602.06% |
| 2023-06-30 | $-4.00 Million | $-4.07 Million | 1.018x | -6.91% |
| 2022-06-30 | $-1.29 Million | $-1.41 Million | 1.093x | -- |